Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

ieved to have superior anticoagulant effects compared to other targets such as thrombin. Portola believes betrixaban will offer several advantages over warfarin and the FXa inhibitors in development, including a long half-life to support once-daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment.

Portola has successfully completed a Phase 2 trial demonstrating betrixaban's proof of clinical concept and a favorable tolerability profile in preventing venous thromboembolism in patients undergoing knee replacement surgery. Later this year, Portola will initiate a Phase 2 clinical study in 500 patients comparing the safety and tolerability of betrixaban to warfarin, the only marketed chronic, oral anticoagulant for stroke prevention in patients with atrial fibrillation.

The other Phase 2 drug candidate is PRT060128, an antiplatelet agent that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit over clopidogrel and other antiplatelet agents in development through its immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola's clinical studies to date with the IV and oral formulations have shown that PRT060128 is well tolerated at high drug levels. Later this year, Portola will initiate a Phase 2 trial comparing the safety, tolerability and efficacy of the IV bolus followed by the oral formulation (60 days of therapy) of PRT060128 to clopidogrel in 800 patients undergoing elective percutaneous coronary interventions (PCI).

Expanding Early Stage Pipeline

Portola is developing a universal Factor Xa inhibitor antidote with the goal of neutralizing the effect of small molecule Factor Xa inhibitors in patients experiencing moderate or major ble
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Stryker Orthopaedics, the Official Joint ... is rounding out its debut year of the relationship ... Scottsdale, AZ. This marks the eleventh tournament ... that the brand has activated on-site with the "Stryker ... fans on the importance of joint health.  ...
(Date:10/30/2014)... , Oct. 30, 2014  Zimmer Holdings, Inc. (NYSE: ... the future executive leadership team and organizational structure of ... transaction.  Zimmer also announced that the combined organization will ... be named Zimmer Biomet, with the new brand to ... closing of the merger.  The future leadership team is ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 2DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 3DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 4DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 5DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 6DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory 7Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 2Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 3Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 4Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 5Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 6Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 7Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 8Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 9Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 10Elsevier is Meeting Today's Medical Students' Needs With Online, Mobile and Print Tools 11
(Date:10/30/2014)... and her research group at the DFG Research Center ... the TU Dresden (CRTD) demonstrated for the first time ... cord in three dimensions from mouse embryonic stem cells. ... interneurons along the dorsal/ventral axis was observed., This study ... " Stem Cell Reports " on 30.10.2014 ., For ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Don Allred ... and health insurance plans for North Carolina residents, is ... office in Burlington’s Holly Hill Mall. The new branch ... agents already helping customers through all facets of the ... , Allred Insurance spokesman Scott Allred couldn’t be happier ...
(Date:10/30/2014)... October 30, 2014 Radio listeners who ... questions about the impact of traditional radio commercials and ... most likely to influence a purchasing decision. , Those ... 525 consumers conducted by radio marketing company CRN International. ... isolating the results of respondents who indicated they have ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Dr. Joseph Furlin ... new website for his practices; OB GYN in Melrose ... . This website contains important information about each of ... well as downloadable patient forms in English and Spanish. ... the service pages on the website provide Dr. Furlin’s patients ...
(Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Allred Insurance Satellite Office Grand Opening 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... There has been a Dutch study which links diets ... E, and zinc to lower odds of developing age-related ... the study can be seen in The Journal of ... van Leeuwen, MD, PhD, and colleagues.,Age-related macular degeneration or ...
... of HIV in the three armed services, particularly the army, ... // for all its personnel serving in the northeast. ... insurgency-affected northeast as well as those returning from the region ... Singh, director general of the Armed Forces Medical Services (AFMS). ...
... pharmaceutical companies are keen to enhance business with India, ... the stringent visa norms. ,Pakistani firms are ... the Chinese, apart from the language barrier. ... though their rates are cheaper than the Indian market," ...
... colleagues, Feinberg School of Medicine have reported in Journal ... // reduces the cardio-respiratory fitness leading to increase in ... risk of cardiovascular diseases. The researchers conducted their survey ... 50 years and below 50 years of age and ...
... Researchers have found that obese people are in increased ... conducted by Professor Michael Belkin and Zohar Habot-Wilner // ... more than 20 reviews and found that risk of ... studies have proved the link between obesity and other ...
... system gets affected by rabies which is transmitted through the ... is required for a person who is bitten by a ... bite from an animal is unprovoked, it is safer to ... for the infection. If found infected, the animal has to ...
Cached Medicine News:Health News:Move to make HIV Tests mandatory For Soldiers In Northeast 2Health News:Pakistan drug companies seek trade ties with India 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: